21 results on '"Miller, Robert S."'
Search Results
2. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
3. Disproportionate impact of COVID-19 disease among racial and ethnic minorities in the U.S. cancer population as seen in CancerLinQ Discovery data.
4. Impact of curated data on electronic quality measure capture rates within CancerLinQ.
5. Low rates of BRCA1 and BRCA2 testing for patients with ovarian cancer in ASCO's CancerLinQ, a real-world database.
6. Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations.
7. Status Update on Data Required to Build a Learning Health System
8. Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice.
9. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.
10. Electronic but overly eclectic: Disciplined EHR data management is needed to automate MIPS reporting.
11. NCI and ASCO CancerLinQ collaboration to advance quality of cancer care and surveillance.
12. Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ database.
13. Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor.
14. Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ.
15. Quantifying interoperability: An analysis of oncology practice electronic health record data variability.
16. Hypertension and use of bevacizumab among patients treated in community settings.
17. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).
18. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
19. TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.
20. Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer
21. Innovations in American Society of Clinical Oncology Practice Guideline Development
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.